Streetbeat News

Price Targets

SLGL

HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Sol-Gel Technologies (NASDAQ:SLGL) but reduced the price target from $12 to $9.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:25 pm

EQ

HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Equillium (NASDAQ:EQ) but has reduced the price target from $5.5 to $4.5.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:25 pm

AEZS

HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on AEterna Zentaris (NASDAQ:AEZS) but reduced the price target from $28 to $15.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:23 pm

ANVS

HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Annovis Bio (NYSE:ANVS) but reduced the price target from $40 to $30.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:22 pm

MGNX

HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on Macrogenics (NASDAQ:MGNX) but has reduced the price target from $14 to $12.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:21 pm

ESPR

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained a $22 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:19 pm

OMGA

HC Wainwright & Co. analyst Robert Burns has reaffirmed a Buy rating on Omega Therapeutics (NASDAQ:OMGA) and increased the price target from $11 to $12.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:18 pm

SVRA

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Savara (NASDAQ:SVRA) and maintained a price target of $6. The reaffirmation of the Buy rating and price target suggests a positive outlook for Savara's stock.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:17 pm

ONCY

HC Wainwright & Co. analyst Patrick Trucchio has maintained a Buy rating on Oncolytics Biotech (NASDAQ:ONCY) but has reduced the price target from $15 to $5.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:16 pm

TPR

JP Morgan analyst Matthew Boss has maintained an Overweight rating on Tapestry (NYSE:TPR) but reduced the price target from $56 to $41.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:05 pm